Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2007-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JC.2007-0938PMID 17878252
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels

  2007cited by this paper
• Positron-emission tomography and assessment of cancer therapy.

  2006cited by this paper
• Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.

  2006cited by this paper
• Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.

  2006cited by this paper
• Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.

  2006cited by this paper
• High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer.

  2005cited by this paper
• Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.

  2005cited by this paper
• Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.

  2005cited by this paper
• Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.

  2005cited by this paper
• Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer

  2004cited by this paper
• Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

  2004cited by this paper
• Impact of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Biochemical Evidence of Recurrent or Residual Medullary Thyroid Cancer

  2004cited by this paper
• Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors.

  2004cited by this paper
• 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.

  2002cited by this paper
• Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas.

  2001cited by this paper
• Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma

  2001cited by this paper
• Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study

  2001cited by this paper
• Current approaches and perspectives in the therapy of medullary thyroid carcinoma

  2001cited by this paper
• Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis

  2000cited by this paper
• The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.

  2000cited by this paper
• The value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with medullary thyroid cancer

  2000cited by this paper
• Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies.

  2000cited by this paper
• Facteurs pronostiques de survie sans récidive clinique dans les cancers médullaires du corps thyroïde : à propos de 52 cas opérés

  1999cited by this paper
• Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study

  1999cited by this paper
• Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.

  1999cited by this paper
• Repeat mediastinal lymph-node dissection for palliation in advanced medullary thyroid carcinoma

  1999cited by this paper
• [Prognostic factors of survival without clinical recurrences in medullary thyroid carcinoma: apropos of 52 operated cases].

  1999cited by this paper
• Surgical strategy for the treatment of medullary thyroid carcinoma.

  1999cited by this paper
• Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.

  1998cited by this paper
• Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours

  1997cited by this paper
• Improved results of cervical reoperation for medullary thyroid carcinoma.

  1997cited by this paper
• Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.

  1996cited by this paper
• Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.

  1996cited by this paper
• Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).

  1995cited by this paper
• Medullary Thyroid Carcinoma: Recent Advances and Management Update

  1995cited by this paper
• Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine

  1995cited by this paper
• Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine

  1994cited by this paper
• Localization of Occult Persisting Medullary Thyroid Carcinoma Before Microsurgical Reoperation: High Sensitivity of Selective Venous Catheterization

  1992cited by this paper
• Medullary carcinoma of the thyroid: current diagnosis and management.

  1991cited by this paper
• Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

  1990cited by this paper
• Recurrent occult medullary thyroid carcinoma detected by MR imaging.

  1989cited by this paper
• Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma.

  1989cited by this paper
• Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.

  1988cited by this paper
• Sonography in the follow-up of 100 patients with thyroid carcinoma.

  1987cited by this paper
• Ultrasound diagnosis of C‐cell carcinoma of the thyroid

  1985cited by this paper
• Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid.

  1984cited by this paper

• Medullary Thyroid Carcinoma: Imaging.

  2025cites this paper
• Patient-Derived Medullary Thyroid Cancer Organoids; a Model for Patient-tailored Drug and PET-Tracer Screening

  2023cites this paper
• Positron Emission Tomography/Computed Tomography in Thyroid Cancer.

  2022cites this paper
• Next-Generation Molecular Imaging of Thyroid Cancer

  2021cites this paper
• PET in medullary thyroid carcinoma

  2021cites this paper
• Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

  2021cites this paper
• State of the art and future directions in the systemic treatment of medullary thyroid cancer

  2021cites this paper
• Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

  2020cites this paper
• Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2

  2020cites this paper
• Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases

  2020cites this paper
• Clinical Relevance of 18F-FDG PET/CT in the Postoperative Follow-up of Patients with History of Medullary Thyroid Cancer

  2020cites this paper
• Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer

  2020cites this paper
• EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma

  2019cites this paper
• F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients

  2019cites this paper
• Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches

  2019cites this paper
• Medullary Thyroid Carcinoma: An Update on Imaging

  2019cites this paper
• Novel PET tracers: added value for endocrine disorders

  2019cites this paper
• Sporadic Medullary Thyroid Cancer

  2018cites this paper
• THE COMBINED USE OF CALCITONIN DOUBLING TIME AND 18F-FDG PET/CT IMPROVES PROGNOSTIC VALUES IN MEDULLARY THYROID CARCINOMA: THE CLINICAL UTILITY OF 18F-FDG PET/CT.

  2017cites this paper
• 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth

  2017cites this paper
• Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

  2016cites this paper
• Medullary Thyroid Carcinoma: Imaging.

  2015cites this paper
• Recurrent spinal metastasis of a sporadic medullary carcinoma of the thyroid after radiation therapy: a case report and review of the literature

  2015cites this paper
• Long-Term Follow-up in Medullary Thyroid Carcinoma.

  2015cites this paper
• Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer.

  2015cites this paper
• Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

  2015cites this paper
• Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.

  2015cites this paper
• Medullary Thyroid Cancer

  2015cites this paper
• [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].

  2014cites this paper
• 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma

  2014cites this paper
• Nuclear medicine imaging of endocrine neoplasms

  2014cites this paper
• Intracystic concentrations of tumour markers for the diagnosis of cystic liver lesions

  2014cites this paper
• Vandétanib, modalités pratiques d’utilisation dans le traitement des patients atteints de cancer médullaire de la thyroïde

  2014cites this paper
• Clinical value of [(18)F]FDG-PET/CT in the detection of metastatic medullary thyroid cancer.

  2014cites this paper
• Update on medullary thyroid cancer.

  2014cites this paper
• Current update on medullary thyroid carcinoma.

  2013cites this paper
• HEREDITARY MEDULLARY THYROID CANCER: TREATMENT, FOLLOW-UP, PROGNOSIS (PART II)

  2013cites this paper
• Multiple Endocrine Neoplasia Type 2 and Bone

  2013cites this paper
• Current understanding and management of medullary thyroid cancer.

  2013cites this paper
• What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?

  2013cites this paper
• Correlation between Calcitonin Levels and [18F]FDG-PET/CT in the Detection of Recurrence in Patients with Sporadic and Hereditary Medullary Thyroid Cancer

  2012cites this paper
• Contemporary nuclear medicine imaging of neuroendocrine tumours.

  2012cites this paper
• Can injection of pentagastrin stimulate the identification of metastases of medullary thyroid carcinoma by (18)F-FDG PET/CT?

  2012cites this paper
• PET Imaging in Recurrent Medullary Thyroid Carcinoma

  2012cites this paper
• Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)

  2012cites this paper
• [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].

  2012cites this paper
• Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma

  2012cites this paper
• 18F‐FDG‐PET and 18F‐FDG‐PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: A systematic review and meta‐analysis

  2012cites this paper
• 2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer

  2012cites this paper
• How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals

  2012cites this paper
• Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma

  2012cites this paper
• Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis

  2012cites this paper
• Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

  2012influential citation
• Evaluación de la eficacia y del impacto clínico de la PET-18F-FDG en el diagnóstico de recurrencia del carcinoma medular de tiroides con calcitonina elevada y pruebas de imagen negativas

  2012cites this paper
• Medullary Thyroid Carcinoma

  2012cites this paper
• Impact of 18F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma

  2011cites this paper
• Surgical management of sporadic medullary thyroid cancer.

  2011cites this paper
• Diagnosis of bone metastasis: recent comparative studies of imaging modalities.

  2011cites this paper
• Genetic and molecular pathophysiology of medullary thyroid cancer.

  2011cites this paper
• Molecular imaging in the management of thyroid cancer.

  2011cites this paper
• Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging.

  2011cites this paper
• La TEP-TDM à la 18F-Dopa aurait-elle un rôle dans le suivi postopératoire des patients atteints de carcinome médullaire de la thyroïde ? Résultats préliminaires de l’expérience strasbourgeoise et revue de la littérature

  2011cites this paper
• Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers

  2011cites this paper
• Traitement chirurgical du cancer médullaire sporadique de la thyroïde

  2011cites this paper
• Detektion okkulter medullärer Schilddrüsenkarzinome bei Patienten einer universitären Schilddrüsen-Ambulanz: Diagnostischer Wert von Calcitonin-Screening, Pentagastrintest und Gastrinrezeptorszintigraphie

  2010cites this paper
• Molecular imaging of neuroendocrine tumors.

  2010cites this paper
• Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer

  2010cites this paper
• The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma

  2010cites this paper
• Role of [18F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer

  2010cites this paper
• PET and PET/CT in endocrine tumours.

  2010cites this paper
• Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F(ab′)2 antibody

  2010cites this paper
• Sporadic medullary thyroid cancer.

  2010cites this paper
• The Clinical Role of Molecular Imaging: Positron Emission Tomography/Computed Tomography and (90)Yttrium-DOTATOC in the Management of Medullary Thyroid Cancer

  2010cites this paper
• F-18 FDG PET detection of a medullary thyroid carcinoma in a patient with metastatic colonic cancer; literature review.

  2009cites this paper
• Multiple endocrine neoplasia type 2

  2009cites this paper
• Toma de decisiones en carcinoma medular de tiroides

  2009cites this paper
• Medullary thyroid carcinoma and biomarkers: past, present and future

  2009cites this paper
• Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide.

  2009cites this paper
• Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer

  2009cites this paper
• Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

  2009cites this paper
• Sporadic and familial medullary thyroid carcinoma: state of the art.

  2009cites this paper
• Artigo de Revisão Taking decisions in thyroid medullary carcinoma

  2009cites this paper
• 18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation

  2008cites this paper
• Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy

  2008cites this paper
• Behind Fluorodeoxy-Glucose: the Role of Positron Emission Tomography/Computed Tomography for Fluorine-18 Labelled PET-Tracer Imaging

  2008cites this paper
• Long‐term prognosis of medullary thyroid carcinoma

  2008cites this paper
• Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels

  2008cites this paper
• Role of PET in medullary thyroid carcinoma.

  2008cites this paper
• MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?

  2008cites this paper
• Radionuclide Imaging of Medullary Carcinoma

  2006cites this paper